ArticleCancers2022

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib's Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion.

Lingying Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.